CN105687277A - Composite for improving immunity and application - Google Patents
Composite for improving immunity and application Download PDFInfo
- Publication number
- CN105687277A CN105687277A CN201610153668.9A CN201610153668A CN105687277A CN 105687277 A CN105687277 A CN 105687277A CN 201610153668 A CN201610153668 A CN 201610153668A CN 105687277 A CN105687277 A CN 105687277A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- immunity
- compositions
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 53
- 239000002131 composite material Substances 0.000 title abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 44
- 239000000843 powder Substances 0.000 claims abstract description 29
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 20
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 15
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 15
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 15
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 15
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 14
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004386 Erythritol Substances 0.000 claims abstract description 11
- 235000019414 erythritol Nutrition 0.000 claims abstract description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 11
- 229940009714 erythritol Drugs 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 58
- 230000036541 health Effects 0.000 claims description 17
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 16
- 229920002307 Dextran Polymers 0.000 claims description 11
- 235000003935 Hippophae Nutrition 0.000 claims description 10
- 241000229143 Hippophae Species 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 235000013402 health food Nutrition 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 5
- 238000010010 raising Methods 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 229940041984 dextran 1 Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 9
- 244000249214 Chlorella pyrenoidosa Species 0.000 abstract 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 abstract 1
- 244000285963 Kluyveromyces fragilis Species 0.000 abstract 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 238000003304 gavage Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000000242 pagocytic effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 230000005180 public health Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 241001328788 Camellia nitidissima Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composite for improving the immunity and application. The composite is prepared from, by weight, 10-30 parts of agaricus blazei murill extract, 10-30 parts of grifola frondosa extract, 10-30 parts of chlorella pyrenoidosa, 5-15 parts of cordyceps militaris extract, 1-10 parts of ginseng extract, 10-20 parts of sea buokthom powder, 1-10 parts of yeast beta-glucose, 1-10 parts of erythritol and 1-5 parts of nutritional yeast powder. It is proved through animal tests that all the raw materials in the composite have an effect on improving the immunity synergistically.
Description
Technical field
The present invention relates to a kind of compositions improving immunity and application。
Background technology
Immunity is the defense mechanism of human body self, it is human bioequivalence and any foreign body (virus, antibacterial etc.) eliminating external intrusion, process the own cells of aging, damage, death, degeneration, and identify and process the ability of vivo mutations cell and virus infected cell。Immunity can be divided into nonspecific immunity and specific immunity: 1, innate immunity, is that people is once being born；2, acquired immunity, is naturally obtain in life process after people is born, or passively obtains by the method for human assistance。
Some special cells of body immune system can by the antibacterial in invasion body, the cell of viral and internal aging death, the cell suddenlyd change and the material causing allergy, swallowed wholly and eliminated, thus maintaining stablizing of internal milieu, keep body health。But body's immunity began to subtract late at about 30 years old, this change be quietly, slowly, be continued for。When immune function of human body is lacked of proper care, or when immune system is unsound, immune system can not normally play protective effect。In the case, very easily causing antibacterial, virus, fungus etc. and infect, therefore hypoimmunity the most directly shows is exactly liable to illness。Often ill, increased the weight of the consumption of body, so generally have a delicate constitution, the reduction of malnutrition, lethargy, fatigue and weak, appetite, the performance such as sleep disorder；Furthermore, it is necessary to be lot more time to recover, and usually recurrent exerbation。If things go on like this can cause that health and intelligent development are bad, also easily bring out major disease。Cause the underlying causes that above-mentioned phenomenon occurs be hypoimmunity or immunity unsound。
Modern society, environmental problem is more and more prominent, and people's operating pressure is big, do not get enough athletic exercise, and then causes that the immunity of people is worse and worse, improves immunity and is called the hot issue that modern is concerned about, substantial amounts of have the health product improving immunity function and arise at the historic moment。At present, common health product kind mainly has: with vitamin and mineral be main component trophism health care products, extract the health product of effective nutritional labeling with natural or rare species for raw material, cross tonic type health product that the animals and plants of medical value are primary raw material with rare Chinese medicine, effective component extracting is made from marine organisms health product or the health product made for raw material with animal foremilk。But, in the existing health product improving immunity, mostly can not have an effect of clear and definite raisings immunity, major part crowd thinks DeGrain after the health product taking raising immunity。
Summary of the invention
It is an object of the invention to overcome the deficiencies in the prior art, it is provided that a kind of compositions that can significantly improve immunity。
Second purpose of the present invention is to provide a kind of compositions improving immunity and improves the application in the health product of immunity or health food in preparation。
3rd purpose of the present invention is to provide the oral formulations comprising above-mentioned composition。
4th purpose of the present invention is to provide the application in the health product or health food of preparation raising immunity of the above-mentioned oral formulations。
Technical scheme is summarized as follows:
A kind of compositions improving immunity, is made up of following component by weight:
Agaricus blazei Murrill extract 10～30 parts, Effects of Extracts of Grifola frondosa on Active 10～30 parts, Chlorella pyrenoidesa 10～30 parts, Cordyceps militaris (L.) Link. extract 5～15 parts, Radix Ginseng extract 1～10 part, Fructus Hippophae powder 10～20 parts, yeast beta-dextran 1～10 part, erythritol 1～10 part and nutrient yeast powder 1～5 part。
Preferably, Agaricus blazei Murrill extract 18 parts, Effects of Extracts of Grifola frondosa on Active 18 parts, Chlorella pyrenoidesa 18 parts, Cordyceps militaris (L.) Link. extract 10 parts, Radix Ginseng extract 5 parts, Fructus Hippophae powder 15 parts, yeast beta-dextran 3 parts, erythritol 5 parts, nutrient yeast powder 2 parts。
Above-mentioned composition application in the health product or health food of preparation raising immunity。
Comprise the oral formulations of above-mentioned composition。
The preferred powder of dosage form of above-mentioned oral formulations, granule, capsule, tablet, pill, drop pill or syrup。
Above-mentioned oral formulations improves the health product of immunity or the application of health food in preparation。
Advantages of the present invention:
Proving through zoopery, in the compositions of the present invention, each raw material share and has the collaborative effect improving immunity。
Detailed description of the invention
Extract is originated:
(1) Agaricus blazei Murrill extract: with Agaricus blazei Murrill for raw material, through water extraction, concentration, dry, pulverize, sieve, the processes such as packaging forms；Product specification is polyoses content 30%。Execution standard is that enterprise puts on record standard: Q/HZK0010S。
(2) Effects of Extracts of Grifola frondosa on Active: with Grifola frondosa for raw material, through water extraction, concentration, dry, pulverize, sieve, the processes such as packaging forms；Product specification is polyoses content 30%。Execution standard is that enterprise puts on record standard: Q/HZK0010S。
(3) Chlorella pyrenoidesa: the Chlorella pyrenoidesa of artificial cultivation by centrifugation, washing, separate, the technique such as dry is made。Chlorella pyrenoidesa is the new resource food that Ministry of Public Health " bulletins about approval 4 kinds of new resource foods such as Chlorella pyrenoidesa " (2012 No. 19) is ratified。
(4) Cordyceps militaris (L.) Link. extract: with Cordyceps militaris (L.) Link. for raw material, through water extraction, concentration, dry, pulverize, sieve, the processes such as packaging forms；Product specification is polyoses content 30%。Execution standard is that enterprise puts on record standard: Q/HZK0010S。
(5) Radix Ginseng extract: with Radix Ginseng for raw material, is solvent with 70% ethanol, through extraction, concentration, chromatography, concentration, dry, pulverize and sieve, mix, the processes such as packaging forms；Product specification is 10:1。Execution standard is that enterprise puts on record standard: Q/610000-G1705211。
(6) Fructus Hippophae powder: with Fructus Hippophae for raw material, the processes such as extracted, concentration, spray drying forms；Product specification is 10:1。Execution standard is GB/T29602。
(7) yeast beta-dextran: with saccharomyces cerevisiae for raw material, the step such as extracted, acid-alkali treatment, spray drying produces。Yeast beta-dextran is the new resource food that Ministry of Public Health " being the bulletin of new resource food about 5 kinds of article such as approval Camellia nitidissima Chi, aobvious arteries and veins Flos Inulaes (Radix Saniculae Astrantifoliae) " (2010 No. 9) is ratified。
(8) erythritol: with glucose for raw material, utilizes that Candida lipolytica is fermented is converted into erythritol。Execution standard is GB26404。
(9) nutrient yeast powder: with saccharomyces cerevisiae for primary raw material, adds the dispensing such as starch, through thermal shock (i.e. heat shock refers to the high-temperature process in the short time), separating-purifying, the product that technique is made such as dries。Execution standard is that enterprise puts on record standard: Q/YB2253S。
Below in conjunction with specific embodiment, the present invention is further illustrated。
Embodiment 1
A kind of compositions improving immunity, it is made up of following component by weight: Agaricus blazei Murrill extract 18 parts, Effects of Extracts of Grifola frondosa on Active 18 parts, Chlorella pyrenoidesa 18 parts, Cordyceps militaris (L.) Link. extract 10 parts, Radix Ginseng extract 5 parts, Fructus Hippophae powder 15 parts, yeast beta-dextran 3 parts, erythritol 5 parts, nutrient yeast powder 2 parts。
Embodiment 2
Agaricus blazei Murrill extract 10 parts, Effects of Extracts of Grifola frondosa on Active 30 parts, Chlorella pyrenoidesa 10 parts, Cordyceps militaris (L.) Link. extract 15 parts, Radix Ginseng extract 1 part, Fructus Hippophae powder 20 parts, yeast beta-dextran 1 part, erythritol 10 parts, nutrient yeast powder 1 part。
Embodiment 3
Agaricus blazei Murrill extract 30 parts, Effects of Extracts of Grifola frondosa on Active 10 parts, Chlorella pyrenoidesa 30 parts, Cordyceps militaris (L.) Link. extract 5 parts, Radix Ginseng extract 10 parts, Fructus Hippophae powder 10 parts, yeast beta-dextran 10 parts, erythritol 1 part, nutrient yeast powder 5 parts。
Embodiment 4
Prepared by a kind of compositions improving immunity:
Weigh the component of each embodiment, mix homogeneously, cross 80 mesh sieves。
Embodiment 5
Comprising the granule of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, make granule according to a conventional method, this granule can as solid beverage, convenient use。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding granule。
Embodiment 6
Comprise the capsule of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, make granule according to a conventional method, granule is loaded capsule。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding capsule。
Embodiment 7
Comprising the tablet of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, make granule according to a conventional method, tablet made by tabletting。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding tablet。
Embodiment 8
Comprise the pill of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, make pill according to a conventional method。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding pill。
Embodiment 9
Comprising the drop pill of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, dripping becomes drop pill according to a conventional method。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding drop pill。
Embodiment 10
Comprise the syrup of a kind of compositions improving immunity of embodiment 1, be that the compositions improving immunity is added pharmaceutically acceptable adjuvant, make syrup according to a conventional method。
A kind of compositions improving immunity of embodiment 2 or embodiment 3 is substituted the compositions of the present embodiment, other same the present embodiment, prepares corresponding syrup。
Embodiment 11
Impact on mouse anti-reflecting fatigue physical signs
According to Ministry of Public Health " health food inspection and technology assessment specification " (2003), 40 mices (are bought in Beijing Vital River Experimental Animals Technology Co., Ltd.；The quality certification number: CXK (capital) 2008-0005, meets conventional animals standard)。Body weight 18g～22g, is randomly divided into 10 groups, often group 10。
Experimental group: embodiment 1, embodiment 2, embodiment 3 compositions being added water and be made into the mixed liquor of lg/mL respectively, gavage gives mice, and gavage amount is lOmL/kg, once a day, amounts to 30 days。
Blank group: deionized water gavage gives mice, gavage amount is lOmL/kg, once a day, amounts to 30 days。
After 30 days, weigh every Mouse Weight respectively, and carry out dislocation place and after death take out spleen, thymus, weigh spleen, thymic weight respectively。Calculate internal organs/weight ratio ((mg/lOg represents)。Result is as shown in table 1:
Table 1 mice physical signs
| Group | Number of animals (only) | Spleen/weight ratio (mg/10g) | Thymus/weight ratio (mg/10g) |
| Blank group | 10 | 42.27±2.63 | 18.21±2.01 |
| Embodiment 1 group | 10 | 42.79±2.87* | 18.76±1.51* |
| Embodiment 2 groups | 10 | 42.56±3.02* | 18.65±1.86* |
| Embodiment 3 groups | 10 | 42.49±2.44* | 18.41±1.52* |
* represent P < 0.05 compared with matched group, there is significant difference。
From data it can be seen that roll over compared with matched group with sky, mice organs/weight ratio is all had no significant effect by the compositions that embodiment 1,2,3 provides, it was shown that mice is had no side effect by compositions provided by the invention。
Embodiment 12
On mouse monokaryon--the impact of macrophage phagocytic function
According to Ministry of Public Health " health food inspection and technology assessment specification " (2003), 100 mices (are bought in Beijing Vital River Experimental Animals Technology Co., Ltd.；The quality certification number: CXK (capital) 2008-0005, meets conventional animals standard)。Body weight 18g～22g, is randomly divided into 10 groups, often group 10。
Experimental group: embodiment 1, embodiment 2, embodiment 3 compositions being added water and be made into the mixed liquor of lg/mL respectively, gavage gives mice, and gavage amount is lOmL/kg, once a day, amounts to 30 days。
Matched group: respectively Agaricus blazei Murrill extract, Effects of Extracts of Grifola frondosa on Active, Chlorella pyrenoidesa, Cordyceps militaris (L.) Link. extract, Radix Ginseng extract, yeast beta-dextran powder are added water and be made into the mixed liquor of lg/mL, gavage gives mice, gavage amount is lOmL/kg, once a day, amounts to 30 days。
Blank group: deionized water gavage gives mice, gavage amount is lOmL/kg, once a day, amounts to 30 days。
Often the group continuous gavage of mice is after 30 days, every mouse peritoneal injects 20% chicken erythrocyte suspension 1mL, after 30min, cervical dislocation is put to death, and is fixed on Mus plate, abdominal skin is cut off in center, through abdominal cavity saline injection 2mL, rotate Mus plate lmin, sucking-off abdominal cavity washing liquid 1mL, mean droplet, on 2 microscope slides, puts 37 DEG C of 30mi of wet box；Take out rinse in normal saline, dry, fixing, GiemsaPBS dyes 3min, and distilled water rinses and dries, microscopy。Calculate phagocytic percentage and phagocytic index。Result is table 2 such as:
Table 2 mouse monokaryon one macrophage phagocytic function
| Group | Number of animals (only) | Phagocytic percentage (%) | Phagocytic index |
| Blank group | 10 | 32.75±4.20 | 1.19±0.17 |
| Embodiment 1 group | 10 | 41.67±6.83* | 1.43±0.23* |
| Embodiment 2 groups | 10 | 39.79±3.85* | 1.38±0.13* |
| Embodiment 3 groups | 10 | 38.44±4.62* | 1.39±0.18* |
| Agaricus blazei Murrill extract group | 10 | 33.13±3.13 | 1.22±0.16 |
| Effects of Extracts of Grifola frondosa on Active group | 10 | 32.89±4.28 | 1.21±0.14 |
| Chlorella pyrenoidesa powder group | 10 | 32.23±3.20 | 1.19±0.27 |
| Cordyceps militaris (L.) Link. extract group | 10 | 33.23±2.58 | 1.22±0.15 |
| Radix Ginseng extract group | 10 | 32.79±3.56 | 1.21±0.21 |
| Yeast beta-dextran powder group | 10 | 34.77±5.12 | 1.23±0.14 |
* represent that compared with matched group P < 0.05 has significant difference。
Result shows:
Compared with blank group, the detected next phagocytic percentage of the compositions that embodiment 1,2,3 provides has significant difference P < 0.05。Phagocytic index has significant difference P < 0.05。
Embodiment 13
Impact on NK cells in mice activity
According to Ministry of Public Health " health food inspection and technology assessment specification " (2003), 100 mices (are bought in Beijing Vital River Experimental Animals Technology Co., Ltd.；The quality certification number: CXK (capital) 2008-0005, meets conventional animals standard)。Body weight 18g～22g, is randomly divided into 10 groups, often group 10。
Experimental group: embodiment 1, embodiment 2, embodiment 3 compositions being added water and be made into the mixed liquor of lg/mL respectively, gavage gives mice, and gavage amount is lOmL/kg, once a day, amounts to 30 days。
Matched group: respectively Agaricus blazei Murrill extract, Effects of Extracts of Grifola frondosa on Active, Chlorella pyrenoidesa, Cordyceps militaris (L.) Link. extract, Radix Ginseng extract, yeast beta-dextran powder are added water and be made into the mixed liquor of lg/mL, gavage gives mice, gavage amount is lOmL/kg, once a day, amounts to 30 days。
Blank group: deionized water gavage gives mice, gavage amount is lOmL/kg, once a day, amounts to 30 days。
The often group continuous gavage of mice after 30 days, cervical dislocation puts to death mice, aseptic takes spleen, is placed in the little plate filling appropriate aseptic Hank's liquid, is torn up by spleen gently with tweezers, filters through 200 eye mesh screens, make single cell suspension standby。Washing cell suspension 2 times with Hank's liquid, each 1000r/min is centrifuged lOmin。Abandon supernatant, cytoplasm is upspring, add 0.5mL aquesterilisa 20s, 0.5mL2 times of Hank's liquid and 8mLHank's liquid is added after splitting erythrocyte, 1000r/min is centrifuged lOmin, resuspended containing 10% calf serum and M work 1640 complete culture solution with 1mL, expect blue dyeing counting viable count (should more than 95%) with platform, finally adjusting cell concentration with RPM work 1640 complete culture solution is 2X107Individual/mL。Take target cell and each 100uL of effector lymphocyte (effect target is than 50:1)), add in U-shaped 96 well culture plates；Target cell Spontaneous release hole adds target cell and each 100uL of culture fluid, and the maximum release aperture of target cell adds target cell and each 100uL of 1%NP40；Above-mentioned every it is all provided with three parallel holes, in 37 DEG C, 5%CO2Incubator is cultivated 4h, then by 96 well culture plates with the centrifugal 5min of 1500r/min, every hole is drawn in 96 well culture plates at the bottom of supernatant 100uL horizontalization, it is simultaneously introduced LDH matrix liquid 100uL, reaction 3min, every hole adds the HCL30uL of lmol/L, measures optical density value (OD) at microplate reader 490nm place, calculating NK cytoactive, result is table 3 such as:
Table 3NK cytoactive
| Group | Number of animals (only) | NK cytoactive (%) |
| Blank group | 10 | 25.84±13.52 |
| Embodiment 1 group | 10 | 29.76±13.65* |
| Embodiment 2 groups | 10 | 28.17±15.38* |
| Embodiment 3 groups | 10 | 27.96±14.01* |
| Agaricus blazei Murrill extract group | 10 | 26.13±13.13 |
| Effects of Extracts of Grifola frondosa on Active group | 10 | 26.19±13.28 |
| Chlorella pyrenoidesa powder group | 10 | 26.23±13.20 |
| Cordyceps militaris (L.) Link. extract group | 10 | 26.23±12.58 |
| Radix Ginseng extract group | 10 | 26.19±13.56 |
| Yeast beta-dextran powder group | 10 | 26.77±15.12 |
* represent compared with blank group, P < 0.05, there is significant difference。
Result shows:
Compared with blank group, the detected next NK cytoactive of the compositions that embodiment 1,2,3 provides has significant difference P < 0.05。
5, conclusion:
Test result indicate that embodiments of the invention 1, embodiment 2, embodiment 3 compositions are improving immunity of organisms compared with blank group, increase the aspect such as body NK cytoactive and macrophage phagocytic function and there is significant difference,
Positive control medicine Agaricus blazei Murrill extract, Effects of Extracts of Grifola frondosa on Active, Chlorella pyrenoidesa, Cordyceps militaris (L.) Link. extract, Radix Ginseng extract, yeast beta-dextran powder (data shows: Fructus Hippophae powder, erythritol, nutrient yeast powder do not improve immunity) are improving immunity of organisms compared with blank group, increase the aspect such as body NK cytoactive and macrophage phagocytic function and have certain effect。
It has been experienced that, between each raw material of the compositions of the present invention, there is synergistic function, it is possible to hypoimmunity mice immune organ is had significant protective effect。
Claims (6)
1. improve a compositions for immunity, it is characterized in that being made up of following component by weight:
Agaricus blazei Murrill extract 10～30 parts, Effects of Extracts of Grifola frondosa on Active 10～30 parts, Chlorella pyrenoidesa 10～30 parts, Cordyceps militaris (L.) Link. extract 5～15 parts, Radix Ginseng extract 1～10 part, Fructus Hippophae powder 10～20 parts, yeast beta-dextran 1～10 part, erythritol 1～10 part and nutrient yeast powder 1～5 part。
2. a kind of compositions improving immunity according to claim 1, it is characterized in that described Agaricus blazei Murrill extract 18 parts, Effects of Extracts of Grifola frondosa on Active 18 parts, Chlorella pyrenoidesa 18 parts, Cordyceps militaris (L.) Link. extract 10 parts, Radix Ginseng extract 5 parts, Fructus Hippophae powder 15 parts, yeast beta-dextran 3 parts, erythritol 5 parts, nutrient yeast powder 2 parts。
3. the compositions of claim 1 or 2 application in the health product or health food of preparation raising immunity。
4. comprise the oral formulations of the compositions of claim 1 or 2。
5. oral formulations according to claim 4, is characterized in that the dosage form of described preparation is powder, granule, capsule, tablet, pill, drop pill or syrup。
6. the oral formulations described in claim 4 or 5 improves the health product of immunity or the application of health food in preparation。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153668.9A CN105687277A (en) | 2016-03-17 | 2016-03-17 | Composite for improving immunity and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153668.9A CN105687277A (en) | 2016-03-17 | 2016-03-17 | Composite for improving immunity and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105687277A true CN105687277A (en) | 2016-06-22 |
Family
ID=56221886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610153668.9A Pending CN105687277A (en) | 2016-03-17 | 2016-03-17 | Composite for improving immunity and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105687277A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107279812A (en) * | 2017-06-16 | 2017-10-24 | 贵州神奇药物研究院 | A kind of health food for improving immunity and preparation method thereof |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| WO2020000015A1 (en) * | 2018-06-29 | 2020-01-02 | Integria Healthcare (Australia) Pty Limited | Immunomodulatory compositions and uses thereof |
| CN110679921A (en) * | 2019-09-10 | 2020-01-14 | 江苏康缘药业股份有限公司 | Composition and beverage for enhancing immunity and preparation method thereof |
| CN111838678A (en) * | 2020-05-27 | 2020-10-30 | 中国科学院合肥物质科学研究院 | Composition for enhancing immunity and application thereof |
| CN112089057A (en) * | 2019-06-18 | 2020-12-18 | 安琪酵母股份有限公司 | Composition containing naked algae powder and yeast powder, preparation method and application |
| CN114052249A (en) * | 2021-10-20 | 2022-02-18 | 龙岩市御龙臻品生物科技有限公司 | Yu-rank fine cordyceps militaris compound powder |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977865A (en) * | 2005-11-30 | 2007-06-13 | 广东省农业科学院农业生物技术研究所 | Method for preparing domestic fungus health care oral liquid |
| CN101797272A (en) * | 2010-02-10 | 2010-08-11 | 广东省微生物研究所 | Fungus compound agent with antifatigue function |
| CN104799286A (en) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | Composition for improving immunity and preparation method of composition |
| CN104839659A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Qi deficiency constitution medical formula food |
-
2016
- 2016-03-17 CN CN201610153668.9A patent/CN105687277A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977865A (en) * | 2005-11-30 | 2007-06-13 | 广东省农业科学院农业生物技术研究所 | Method for preparing domestic fungus health care oral liquid |
| CN101797272A (en) * | 2010-02-10 | 2010-08-11 | 广东省微生物研究所 | Fungus compound agent with antifatigue function |
| CN104839659A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Qi deficiency constitution medical formula food |
| CN104799286A (en) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | Composition for improving immunity and preparation method of composition |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107279812A (en) * | 2017-06-16 | 2017-10-24 | 贵州神奇药物研究院 | A kind of health food for improving immunity and preparation method thereof |
| WO2020000015A1 (en) * | 2018-06-29 | 2020-01-02 | Integria Healthcare (Australia) Pty Limited | Immunomodulatory compositions and uses thereof |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| CN112089057A (en) * | 2019-06-18 | 2020-12-18 | 安琪酵母股份有限公司 | Composition containing naked algae powder and yeast powder, preparation method and application |
| CN110679921A (en) * | 2019-09-10 | 2020-01-14 | 江苏康缘药业股份有限公司 | Composition and beverage for enhancing immunity and preparation method thereof |
| CN111838678A (en) * | 2020-05-27 | 2020-10-30 | 中国科学院合肥物质科学研究院 | Composition for enhancing immunity and application thereof |
| CN114052249A (en) * | 2021-10-20 | 2022-02-18 | 龙岩市御龙臻品生物科技有限公司 | Yu-rank fine cordyceps militaris compound powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687277A (en) | Composite for improving immunity and application | |
| CN104826087B (en) | Compound Moringa polypeptide and its preparation method and application | |
| US10681921B2 (en) | Artificial diet for ghost moth larvae and preparation method thereof | |
| CN104623122B (en) | A kind of biological agent and preparation method thereof with anti-fatigue effect | |
| CN107343584A (en) | Fermented beverage and preparation method with anti-fatigue effect | |
| CN101485463A (en) | Natural product composing prescription with various health-care efficacies | |
| CN101904887A (en) | Application of Saussurea involucrata culture in food and anti-inflammatory analgesic medicine | |
| CN101297704B (en) | Health care food for protecting liver and manufacturing method thereof | |
| CN107279984A (en) | Technology of preparing with the gentle physical fatigue functional health product of strengthen immunity | |
| CN101810657B (en) | American ginseng contained composition and American ginseng tea drink | |
| CN102524799A (en) | Protein powder for improving organism immunity and preparation method thereof | |
| CN102150859A (en) | Composition with functions of relieving physical fatigue and improving memory as well as preparation method and application thereof | |
| CN106036325A (en) | Fructus lycii enzyme and preparation method thereof | |
| CN103550399B (en) | Health-care food for relieving physical fatigue, and preparation method thereof | |
| CN109232758B (en) | Pleurotus citrinopileatus mushroom bran polysaccharide and extraction process and application thereof | |
| Wang et al. | Antifatigue effects of peptide isolated from sheep placenta | |
| CN103932179B (en) | A kind of health food and two-step fermentation preparation method thereof releasing the pressure and protect liver | |
| CN104800298A (en) | Traditional Chinese medicine granular preparation for treating gout and preparation method thereof | |
| CN104585778A (en) | Albumen powder for improving organism immunity and preparation method of albumen powder | |
| CN103893223A (en) | Low-temperature lucid ganoderma processing method | |
| CN107095974A (en) | A kind of hypoglycemic composition | |
| CN103255071B (en) | Yeast strain and method for brewing cordyceps sinensis wine by using same | |
| CN101015345A (en) | Health-care food with hypoxia-resistant and immunity-enhancing functions and its preparing process | |
| CN101530209A (en) | A health-care food capable of adjusting blood fat and protecting liver and preparation method thereof | |
| CN106912926A (en) | A kind of composition health food and its preparation technology containing pseudo-ginseng, ginseng and Shorthorned Epimedium P.E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160622 |
|
| WD01 | Invention patent application deemed withdrawn after publication |